Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 29, 2023
Discovery & Translation
Turning cancer drivers into cell death drivers; plus LNPs to edit stem cells and more
BioCentury’s roundup of translational innovations
BioCentury | Feb 10, 2023
Discovery & Translation
Targeting PIKFYVE and SYF2 for ALS; plus new protein degraders and more
BioCentury's roundup of translational news
BioCentury | Dec 5, 2020
Translation in Brief
James Wilson developing gene therapy version of Regeneron COVID mAb cocktail; plus an oncolytic adenovirus, MapLight-Michael J. Fox Foundation and more
BioCentury’s roundup of translational news
BioCentury | Oct 8, 2020
Product Development
COVAX nears $2B fund-raising goal for equitable vaccine distribution; plus Novartis-Merck KGaA, 10x Genomics, Alkermes, UCB-Aetion, Janpix, BeiGene-BioAtla, Phenomic AI
COVAX nearing $2B fund-raising goal for equitable vaccine distributionThe U.K., Canada, Germany, Italy and Sweden pledged $958 million to Gavi’s COVID-19 Vaccines Advance Market Commitment
BioCentury | Mar 15, 2019
Tools & Techniques
Synthetic solutions for immuno-oncology
How Synthorx is harnessing synthetic DNA to enhance biologics
BioCentury | Mar 8, 2019
Emerging Company Profile
Janpix picks STAT inhibitors for blood cancers
How Janpix’s small molecules are specific for STAT3 and STAT5
BioCentury | Aug 4, 2016
Product R&D
Antibiotic wisdom
A new infection diagnostic could smarten antibiotic use
Items per page:
1 - 10 of 18